Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.

Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E.

Cancers (Basel). 2019 Oct 24;11(11). pii: E1641. doi: 10.3390/cancers11111641.

2.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

3.

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.

Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2019 Sep 19. pii: jclinpath-2019-206127. doi: 10.1136/jclinpath-2019-206127. [Epub ahead of print]

PMID:
31537627
4.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

5.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
6.

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.

Fumagalli C, Catania C, Ranghiero A, Bosi C, Viale G, de Marinis F, Barberis M, Guerini-Rocco E.

J Clin Med. 2019 Jan 18;8(1). pii: E112. doi: 10.3390/jcm8010112.

7.

Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.

De Marinis F, Barberis M, Barbieri V, Marchianò A, Gasparini S, Migliorino MR, Romano G, Spinnato F, Vitiello F, Gridelli C.

Expert Rev Respir Med. 2019 Mar;13(3):217-228. doi: 10.1080/17476348.2019.1569517. Epub 2019 Jan 24.

PMID:
30640563
8.

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.

Fumagalli C, Guerini-Rocco E, Vacirca D, Passaro A, Marinis F, Barberis M.

Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027. No abstract available.

PMID:
30185137
9.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A.

Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18.

10.

Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.

De Luca C, Rappa AG, Gragnano G, Malapelle U, Troncone G, Barberis M.

J Clin Pathol. 2018 Aug;71(8):745-750. doi: 10.1136/jclinpath-2018-205197. Epub 2018 May 24.

PMID:
29798838
11.

Letter to the Editor.

Fumagalli C, Casadio C, Barberis M, Guarize J, Guerini-Rocco E.

Clin Lung Cancer. 2018 Jul;19(4):e439-e440. doi: 10.1016/j.cllc.2018.03.001. Epub 2018 Mar 12. No abstract available.

PMID:
29606366
12.

MicroRNA expression profile in primary lung cancer cells lines obtained by endobronchial ultrasound transbronchial needle aspiration.

Guarize J, Bianchi F, Marino E, Belloni E, Vecchi M, Donghi S, Lo Iacono G, Casadio C, Cuttano R, Barberis M, Di Fiore PP, Petrella F, Spaggiari L.

J Thorac Dis. 2018 Jan;10(1):408-415. doi: 10.21037/jtd.2017.12.69.

13.

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.

Breast Cancer Res Treat. 2018 Jul;170(2):351-360. doi: 10.1007/s10549-018-4767-1. Epub 2018 Mar 27.

PMID:
29589138
14.

Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.

Guerini-Rocco E, Passaro A, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M.

Arch Pathol Lab Med. 2018 Apr;142(4):465-473. doi: 10.5858/arpa.2017-0158-RA. Review.

PMID:
29565206
15.

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.

Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.

PMID:
29535211
16.

Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

Cavalcante P, Marcuzzo S, Franzi S, Galbardi B, Maggi L, Motta T, Ghislandi R, Buzzi A, Spinelli L, Novellino L, Baggi F, Antozzi C, Conforti F, De Pas TM, Barberis M, Bernasconi P, Mantegazza R.

Oncotarget. 2017 Sep 8;8(56):95432-95449. doi: 10.18632/oncotarget.20731. eCollection 2017 Nov 10.

17.

The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

Fazio N, Ungaro A, Spada F, Cella CA, Pisa E, Barberis M, Grana C, Zerini D, Bertani E, Ribero D, Funicelli L, Bonomo G, Ravizza D, Guarize J, De Marinis F, Petrella F, Del Signore E, Pelosi G, Spaggiari L.

J Thorac Dis. 2017 Nov;9(Suppl 15):S1501-S1510. doi: 10.21037/jtd.2017.06.14. Review.

18.

External quality assessment for EGFR mutations in Italy: improvements in performances over the time.

Normanno N, Fenizia F, Castiglione F, Barberis M, Taddei GL, Truini M, De Rosa G, Pinto C, Marchetti A.

ESMO Open. 2017 May 26;2(2):e000160. doi: 10.1136/esmoopen-2017-000160. eCollection 2017.

19.

Metastatic and non-metastatic lymph nodes: quantification and different distribution of iodine uptake assessed by dual-energy CT.

Rizzo S, Radice D, Femia M, De Marco P, Origgi D, Preda L, Barberis M, Vigorito R, Mauri G, Mauro A, Bellomi M.

Eur Radiol. 2018 Feb;28(2):760-769. doi: 10.1007/s00330-017-5015-5. Epub 2017 Aug 23.

PMID:
28835993
20.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.

Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.

J Thorac Oncol. 2017 Nov;12(11):1654-1663. doi: 10.1016/j.jtho.2017.07.031. Epub 2017 Aug 14.

Supplemental Content

Loading ...
Support Center